Prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) has been extensively used in the management of patients with prostate cancer. This tracer also offers an important example of the concept of theranostics. However, PSMA expression has also been reported previously in other malignancies such as bladder, breast, gastric, colon, rectum, lung, renal cell carcinoma, hepatocellular carcinoma, multiple myeloma, and follicular lymphoma and in few nonneoplastic conditions.\[[@ref1][@ref2][@ref3][@ref4][@ref5][@ref6][@ref7][@ref8][@ref9]\] Very few studies have shown expression of PSMA in neuroendocrine tumors (NETs).\[[@ref10]\] It is well known from some earlier studies that PSMA expression is seen in the endothelium of tumor neovasculature. Since NETs have very high vascularity, PSMA expression may be seen in the same. In this case, PSMA-PET-CT showed uptake in the primary tumor in the pancreas and metastatic liver lesions. The uptake was high in the periphery of the tumor concordant with the expected distribution of neovasculature. However, the intensity of the uptake was low as compared to 68Ga-DOTANOC. The number of lesions seen on PSMA-PET/CT was much less than that seen on DOTANOC-PET/CT \[[Figure 1](#F1){ref-type="fig"}\]. However, it remains to be seen how much uptake will be seen in high-grade NETs which are known to be poorly DOTANOC avid. This finding may encourage researchers to consider this modality from the theranostic point of view in a disease with limited treatment options.
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